A New E3 Ligase Implicated in Protein Quality Control and Neurodegeneration

一种与蛋白质质量控​​制和神经变性有关的新 E3 连接酶

基本信息

  • 批准号:
    8787516
  • 负责人:
  • 金额:
    $ 41.45万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-01-15 至 2015-12-31
  • 项目状态:
    已结题

项目摘要

7. PROJECT SUMMARY Background and relevance: The goal of this basic research proposal is to better understand the causes of neurodegenerative disorders at the molecular level. Among the best known examples are Alzheimer's, Parkinson's and Huntington's diseases, and Amyotrophic Lateral Sclerosis (ALS). Neurodegenerative diseases are incurable and debilitating conditions with increasing prevalence, and without their pathogenic mechanisms being elucidated in sufficient detail, our ability to generate a rationale for corrective therapeutic interventions is greatly limited. We had previously characterized a novel mouse model of neurodegeneration caused by mutation of the LISTER gene. Consistent with an important biological function, this gene is conserved in all organisms from yeast to humans. Accordingly, we have been utilizing various models to discover the gene function and how defects in this function may lead to the disease. The LISTER gene encodes a protein that acts as an E3 ubiquitin ligase, named Listerin. More recently, using yeast we discovered a function for Listerin that is consistent with a role in neurodegeneration in mammals: it functions in a process known as protein quality control whereby aberrant proteins are targeted for degradation. Specifically, its targets are proteins encoded by defective mRNA lacking stop codons ("non-stop proteins"). Listerin functions by tagging those aberrant proteins with molecules of ubiquitin (ubiquitination), which often acts as a destruction signal. Mutation of Listerin causes those toxic proteins to accumulate. With the proposed research we plan to specify the features of Listerin-mediated ubiquitination and expand the findings towards disease. Objective/Hypothesis: Our main hypotheses are that (a) Listerin acts in protein quality control by ubiquitinating non-stop polypeptides stalled in ribosomes, and (b) defective Listerin-mediated degradation leads to the formation of protein aggregates and inclusions, which are hallmarks of neurodegeneration. The Specific Aims are to characterize Listerin's function in non-stop protein degradation, to investigate the extent of conservation of Listerin's function in protein quality control, and to investigate how defects in this function lead to neurodegeneration. Our long-term objective is to help elucidate molecular mechanisms involved in the pathogenesis of human neurodegenerative disease. Study design: We will use biochemistry and yeast molecular genetics to specify how the E3 recognizes its specific target substrates; mammalian tissue culture and biochemistry to investigate the regulation of non-stop protein degradation by mammalian Listerin and biochemistry and cell biology to study the consequences of non-stop protein accumulation in cells.
7. 项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CLAUDIO A.P. JOAZEIRO其他文献

CLAUDIO A.P. JOAZEIRO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CLAUDIO A.P. JOAZEIRO', 18)}}的其他基金

FASEB SRC: The Ubiquitin & Ub-like proteins Conference: Cell Functions and Therapeutic Targeting
FASEB SRC:泛素
  • 批准号:
    10462962
  • 财政年份:
    2022
  • 资助金额:
    $ 41.45万
  • 项目类别:
A New E3 Ligase Implicated in Protein Quality Control and Neurodegeneration
一种与蛋白质质量控​​制和神经变性有关的新 E3 连接酶
  • 批准号:
    8410088
  • 财政年份:
    2012
  • 资助金额:
    $ 41.45万
  • 项目类别:
Small Molecule Inhibitors of Mdm2 E3 Ubiquitin Ligase Activity for Cancer Therapy
Mdm2 E3 泛素连接酶活性的小分子抑制剂用于癌症治疗
  • 批准号:
    8616725
  • 财政年份:
    2012
  • 资助金额:
    $ 41.45万
  • 项目类别:
Small Molecule Inhibitors of Mdm2 E3 Ubiquitin Ligase Activity for Cancer Therapy
Mdm2 E3 泛素连接酶活性的小分子抑制剂用于癌症治疗
  • 批准号:
    8434835
  • 财政年份:
    2012
  • 资助金额:
    $ 41.45万
  • 项目类别:
A New E3 Ligase Implicated in Protein Quality Control and Neurodegeneration
一种与蛋白质质量控​​制和神经变性有关的新 E3 连接酶
  • 批准号:
    8590232
  • 财政年份:
    2012
  • 资助金额:
    $ 41.45万
  • 项目类别:
Small Molecule Inhibitors of Mdm2 E3 Ubiquitin Ligase Activity for Cancer Therapy
Mdm2 E3 泛素连接酶活性的小分子抑制剂用于癌症治疗
  • 批准号:
    9055550
  • 财政年份:
    2012
  • 资助金额:
    $ 41.45万
  • 项目类别:
A New E3 Ligase Implicated in Protein Quality Control and Neurodegeneration
一种与蛋白质质量控​​制和神经变性有关的新 E3 连接酶
  • 批准号:
    8292845
  • 财政年份:
    2012
  • 资助金额:
    $ 41.45万
  • 项目类别:
Small Molecule Inhibitors of Mdm2 E3 Ubiquitin Ligase Activity for Cancer Therapy
Mdm2 E3 泛素连接酶活性的小分子抑制剂用于癌症治疗
  • 批准号:
    8238648
  • 财政年份:
    2012
  • 资助金额:
    $ 41.45万
  • 项目类别:
Small Molecule Inhibitors of Mdm2 E3 Ubiquitin Ligase Activity for Cancer Therapy
Mdm2 E3 泛素连接酶活性的小分子抑制剂用于癌症治疗
  • 批准号:
    8815096
  • 财政年份:
    2012
  • 资助金额:
    $ 41.45万
  • 项目类别:
STRUCTURE OF AN E3 LIGASE COMPLEX
E3 连接酶复合物的结构
  • 批准号:
    8362470
  • 财政年份:
    2011
  • 资助金额:
    $ 41.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了